"Novartis’ Cosentyx shows no benefit in Phase III GCA trial" was originally created and published by Clinical Trials Arena, a ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan ...

Tremfya and Cosentyx for Psoriasis Treatment. Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis ...

FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...

Novartis’ Cosentyx fails to beat Humira in a head-to-head psoriatic arthritis trial, potentially handing an advantage to rival Taltz from Eli Lilly ...

Cosentyx for HS is approved for monthly administration, with optional two-week dosing. That’s backed by two Phase 3 trials, SUNSHINE and SUNRISE. The primary endpoint in both was a hidradenitis ...